External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study

Conclusion: Our study evaluated the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors (progression status, symptoms, tumor site, specific metastases, and analytical data).. Our results indicate that both octreotide LAR and lanreotide autogel h ad a similar effect on PFS. Consequently, both represent valid alternatives in patients with well-differentiated, metastatic GEP-NENs.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research